ArticleAmerican journal of epidemiology2016
Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer.
Article in American journal of epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.Cancer medicine · 2020Trial
- Trial
- Inflammatory bowel disease and prostate cancer: from epidemiological controversy to mechanistic hypotheses.Frontiers in immunology · 2026Review
- Sexual dimorphism in colon is mediated by an androgen-IL33Cell & bioscience · 2025Article
- Influence of biological sex in inflammatory bowel diseases.Nature reviews. Gastroenterology & hepatology · 2025Review
- Quality of life and supportive care needs in prostate cancer: the impact of treatment received and care service utilization among Māori and non-Māori patients in New Zealand.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The Interplay between Androgen and Gut Microbiota: Is There a Microbiota-Gut-Testis Axis.Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.Research and reports in urology · 2022Review
- Article
- Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study.Journal of gastroenterology · 2019Article
- Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.Prostate cancer and prostatic diseases · 2019Article
- Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.Drug safety · 2019Article
- Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.International urology and nephrology · 2019Article
- No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.Therapeutics and clinical risk management · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer. By lowering androgen levels, ADT inhibits the progression of prostate cancer, but it may also affect gut autoimmunity. We investigated the association between ADT and the incidence of inflammatory bowel disease using a cohort of 31,842 men newly diagnosed with prostate cancer between 1988 and 2014, identified in the United Kingdom Clinical Practice Research Datalink. Exposure to ADT was treated as a time-varying variable and lagged by 1 year to account for diagnostic delays, with nonuse as the reference category. During 133,018 person-years of follow-up, 48 men were newly diagnosed with ulcerative colitis (incidence rate (IR) = 36/100,000 person-years (PY)) and 12 were diagnosed with Crohn's disease (IR = 9/100,000 PY). In Cox proportional hazards models, ADT was associated with a decreased risk of ulcerative colitis (IR = 24/100,000 PY vs. IR = 50/100,000 PY; hazard ratio = 0.52, 95% confidence interval: 0.28, 0.99) and a nonsignificant decreased risk of Crohn's disease (hazard ratio = 0.38, 95% confidence interval: 0.11, 1.37). These findings indicate that the use of ADT may be associated with intestinal autoimmunity. Further research is warranted to replicate these findings and assess their clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.